A Phase II, Double-Blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Tetravalent Dengue Vaccine With Two Different Serotype 2 Potencies in an Adult Population in Singapore
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2017
At a glance
- Drugs TAK 003 (Primary)
- Indications Dengue
- Focus Pharmacodynamics
- Sponsors Takeda
- 12 Oct 2017 Status changed from active, no longer recruiting to completed.
- 15 Sep 2017 Planned End Date changed from 31 Aug 2017 to 19 Sep 2017.
- 15 Sep 2017 Planned primary completion date changed from 31 Aug 2017 to 19 Sep 2017.